Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)

Trial Profile

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Blepharoptosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors RevitaLid
  • Most Recent Events

    • 11 Jan 2019 Planned End Date changed from 30 Jan 2019 to 28 Mar 2019.
    • 11 Jan 2019 Planned primary completion date changed from 16 Jan 2019 to 14 Mar 2019.
    • 11 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top